Hyaluronic Acid (Hyaluronan) |
|
HA-101 | Hyaluronic Acid, MW 10k |
HA-102 | Hyaluronic Acid, MW 50k |
HA-103 | Hyaluronic Acid, MW 250k |
HA-104 | Hyaluronic Acid, MW 750k |
HA-105 | Hyaluronic Acid, MW 1,000k |
HA-106 | Hyaluronic Acid, MW 1,500k |
HA-107 | Hyaluronic Acid, MW 2,500k |
Description:
High purity Hyaluronic Acid (HA) is manufactured by bacterial fermentation. HA has carboxylic acid groups that can be used for bioconjugation or further derivatization using amide coupling reaction with primary amines.
References:
1) Synergistic antitumor activity of camptothecin–doxorubicin combinations and their conjugates with hyaluronic acid, Journal of Controlled Release, 2015, 210, 198–207. Text.
2. Reloadable multidrug capturing delivery system for targeted ischemic disease treatment, Science Translational Medicine,2016, 8, 365, 365ra160, Text.
3. Targeted delivery of hyaluronic acid to the ocular surface by a polymer-peptide conjugate system for dry eye disease, Acta Biomaterialia, Volume 55, 2017, 163-171, Text.
4. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer, Journal of Controlled Release, 2017, doi 10.1016/j.jconrel.2017.08.016, Text.
5. Harnessing the Versatility of Bacterial Collagen to Improve the Chondrogenic Potential of Porous Collagen Scaffolds, Adv Healthc Mater. 2016;5(13):1656-66, Text.
6. Supramolecular Hydrogels Based on MPEG-Grafted Hyaluronic Acid and α-CD Containing HP-β-CD/Simvastatin Enhance Osteogenesis In Vivo, Journal of Nanoscience and Nanotechnology 17(1):217-223, Text.
7. Low-molecular-weight polymer–drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations, Nanomedicine, Vol. 11, No. 9, Text.
8. The influence of hyaluronan on the structure of a DPPC—bilayer under high pressures, Colloids and Surfaces B: Biointerfaces 142, 2016, 230-238, Text.